BiotechTube
Home/Ajax Therapeutics/Martin Vogelbaum
MV

Martin Vogelbaum

Chief Executive Officer, Co-founder

Ajax Therapeutics

Therapeutic Areas

Hematologic CancersMyeloproliferative NeoplasmsMyelofibrosis

Ajax Therapeutics Pipeline

DrugIndicationPhase
AJ1-11095Myelofibrosis (Primary, Post-Polycythemia Vera, Post-Essential Thrombocythemia)Phase 1

Leadership Team at Ajax Therapeutics

DP
David P. Steensma, MD, FACP
Chief Medical Officer
View full Ajax Therapeutics profile